OMONTYS
Post-LOENDAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Mar 2012
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMONTYS is an intravenous and subcutaneous solution approved by the FDA in March 2012 as an NDA product. The specific indication and mechanism of action are not publicly detailed in available data. It is administered as a sterile solution for parenteral use.
Post-LOEPost-LOE
Post-LOE status indicates a mature, stable brand facing competitive pressure; commercial teams typically operate in maintenance mode with emphasis on market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on OMONTYS at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.